Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | PRKACG | P22612 | 1/20 | 0.34 |
| ▸ | PRKACB | P22694 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19580550 | 0.80 | NISCH (0.40) | PRKACAPRKACGPRKACB | |
| SCHEMBL19580707 | 0.80 | NISCH (0.40) | PRKACAPRKACGPRKACB | |
| SCHEMBL24540730 | 0.80 | GPR174 (0.38) | PRKACAPRKACGPRKACBACVR1ATR | |
| Hydrochloric Acid SCHEMBL27174165 | 0.79 | NISCH (0.39) | PRKACAPRKACGPRKACB | |
| SCHEMBL29761449 | 0.79 | TRPV4 (0.39) | PRKACAPRKACGPRKACBACVR1ATR | |
| Hydrochloric Acid SCHEMBL29650845 | 0.79 | NISCH (0.39) | PRKACAPRKACGPRKACB | |
| SCHEMBL17525143 | 0.79 | TRPV4 (0.39) | PRKACAPRKACGPRKACBACVR1ATR | |
| SCHEMBL24540921 | 0.79 | TRPV4 (0.39) | PRKACAPRKACGPRKACBACVR1ATR | |
| SCHEMBL20038413 | 0.74 | ACVR1 (0.41) | PRKACAPRKACGPRKACBACVR1ATR | |
| SCHEMBL20037455 | 0.74 | DRD2 (0.48) | PRKACAPRKACGPRKACBACVR1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4263545-B1 | PRMT5 INHIBITORS | AMGEN INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2022132914-A1 | PRMTS INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | PRKACA 1272/4885PRKACG 1061/4885PRKACB 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.